This week in therapeutics




Licensing status

Publication and contact information

Endocrine/metabolic disease

Obesity; metabolic syndrome

Potassium channel Kv1.3 (KCNA3)

Mouse studies suggest the KCNA3-inhibiting peptide ShK-186 could help treat obesity or metabolic syndrome. In a mouse model for diet-induced obesity, ShK-186 led to less weight gain than vehicle. In the mouse obesity model, ShK-186 activated metabolism in brown adipose and improved peripheral insulin sensitivity. Next steps include investigating ShK-186 in obesity-related indications in humans.
Kineta Inc. has completed Phase Ia testing of ShK-186 in autoimmune diseases.

SciBX 6(25); doi:10.1038/scibx.2013.628
Published online June 27, 2013

Patented; licensed to Kineta

Upadhyay, S.K. et al. Proc. Natl. Acad. Sci. USA; published online May 31, 2013;
Contact: K. George Chandy, University of California, Irvine, Calif.